The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Familial Amyloid Polyneuropathy Market Research Report 2025
Synopsis
Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid neuropathy are a rare group of autosomal dominant diseases caused by the deposition of protein and/or amyloid fibrils around the peripheral nerves and in various tissues, including the heart muscle.
The global Familial Amyloid Polyneuropathy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Globally, development of new drugs for treatment of familial amyloid polyneuropathy, and rise in the prevalence of familial amyloid polyneuropathy are the prime growth drivers of familial amyloid polyneuropathy market.
This report aims to provide a comprehensive presentation of the global market for Familial Amyloid Polyneuropathy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Familial Amyloid Polyneuropathy.
Report Scope
The Familial Amyloid Polyneuropathy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Familial Amyloid Polyneuropathy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Familial Amyloid Polyneuropathy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
GSK
Ionis
Alnylam
Corino Therapeutics
Proclara Bioscience
Arcturus Therapeutics
Segment by Type
FAP-I
FAP-II
FAP-III
FAP-IV
Segment by Application
Hospitals and Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Familial Amyloid Polyneuropathy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid neuropathy are a rare group of autosomal dominant diseases caused by the deposition of protein and/or amyloid fibrils around the peripheral nerves and in various tissues, including the heart muscle.
The global Familial Amyloid Polyneuropathy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Globally, development of new drugs for treatment of familial amyloid polyneuropathy, and rise in the prevalence of familial amyloid polyneuropathy are the prime growth drivers of familial amyloid polyneuropathy market.
This report aims to provide a comprehensive presentation of the global market for Familial Amyloid Polyneuropathy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Familial Amyloid Polyneuropathy.
Report Scope
The Familial Amyloid Polyneuropathy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Familial Amyloid Polyneuropathy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Familial Amyloid Polyneuropathy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
GSK
Ionis
Alnylam
Corino Therapeutics
Proclara Bioscience
Arcturus Therapeutics
Segment by Type
FAP-I
FAP-II
FAP-III
FAP-IV
Segment by Application
Hospitals and Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Familial Amyloid Polyneuropathy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Familial Amyloid Polyneuropathy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 FAP-I
1.2.3 FAP-II
1.2.4 FAP-III
1.2.5 FAP-IV
1.3 Market by Application
1.3.1 Global Familial Amyloid Polyneuropathy Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals and Clinics
1.3.3 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Familial Amyloid Polyneuropathy Market Perspective (2019-2030)
2.2 Familial Amyloid Polyneuropathy Growth Trends by Region
2.2.1 Global Familial Amyloid Polyneuropathy Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Familial Amyloid Polyneuropathy Historic Market Size by Region (2019-2024)
2.2.3 Familial Amyloid Polyneuropathy Forecasted Market Size by Region (2025-2030)
2.3 Familial Amyloid Polyneuropathy Market Dynamics
2.3.1 Familial Amyloid Polyneuropathy Industry Trends
2.3.2 Familial Amyloid Polyneuropathy Market Drivers
2.3.3 Familial Amyloid Polyneuropathy Market Challenges
2.3.4 Familial Amyloid Polyneuropathy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Familial Amyloid Polyneuropathy Players by Revenue
3.1.1 Global Top Familial Amyloid Polyneuropathy Players by Revenue (2019-2024)
3.1.2 Global Familial Amyloid Polyneuropathy Revenue Market Share by Players (2019-2024)
3.2 Global Familial Amyloid Polyneuropathy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Familial Amyloid Polyneuropathy Revenue
3.4 Global Familial Amyloid Polyneuropathy Market Concentration Ratio
3.4.1 Global Familial Amyloid Polyneuropathy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Familial Amyloid Polyneuropathy Revenue in 2023
3.5 Familial Amyloid Polyneuropathy Key Players Head office and Area Served
3.6 Key Players Familial Amyloid Polyneuropathy Product Solution and Service
3.7 Date of Enter into Familial Amyloid Polyneuropathy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Familial Amyloid Polyneuropathy Breakdown Data by Type
4.1 Global Familial Amyloid Polyneuropathy Historic Market Size by Type (2019-2024)
4.2 Global Familial Amyloid Polyneuropathy Forecasted Market Size by Type (2025-2030)
5 Familial Amyloid Polyneuropathy Breakdown Data by Application
5.1 Global Familial Amyloid Polyneuropathy Historic Market Size by Application (2019-2024)
5.2 Global Familial Amyloid Polyneuropathy Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Familial Amyloid Polyneuropathy Market Size (2019-2030)
6.2 North America Familial Amyloid Polyneuropathy Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Familial Amyloid Polyneuropathy Market Size by Country (2019-2024)
6.4 North America Familial Amyloid Polyneuropathy Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Familial Amyloid Polyneuropathy Market Size (2019-2030)
7.2 Europe Familial Amyloid Polyneuropathy Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Familial Amyloid Polyneuropathy Market Size by Country (2019-2024)
7.4 Europe Familial Amyloid Polyneuropathy Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Familial Amyloid Polyneuropathy Market Size (2019-2030)
8.2 Asia-Pacific Familial Amyloid Polyneuropathy Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Familial Amyloid Polyneuropathy Market Size by Region (2019-2024)
8.4 Asia-Pacific Familial Amyloid Polyneuropathy Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Familial Amyloid Polyneuropathy Market Size (2019-2030)
9.2 Latin America Familial Amyloid Polyneuropathy Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Familial Amyloid Polyneuropathy Market Size by Country (2019-2024)
9.4 Latin America Familial Amyloid Polyneuropathy Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Familial Amyloid Polyneuropathy Market Size (2019-2030)
10.2 Middle East & Africa Familial Amyloid Polyneuropathy Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Familial Amyloid Polyneuropathy Market Size by Country (2019-2024)
10.4 Middle East & Africa Familial Amyloid Polyneuropathy Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Familial Amyloid Polyneuropathy Introduction
11.1.4 Pfizer Revenue in Familial Amyloid Polyneuropathy Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 GSK
11.2.1 GSK Company Detail
11.2.2 GSK Business Overview
11.2.3 GSK Familial Amyloid Polyneuropathy Introduction
11.2.4 GSK Revenue in Familial Amyloid Polyneuropathy Business (2019-2024)
11.2.5 GSK Recent Development
11.3 Ionis
11.3.1 Ionis Company Detail
11.3.2 Ionis Business Overview
11.3.3 Ionis Familial Amyloid Polyneuropathy Introduction
11.3.4 Ionis Revenue in Familial Amyloid Polyneuropathy Business (2019-2024)
11.3.5 Ionis Recent Development
11.4 Alnylam
11.4.1 Alnylam Company Detail
11.4.2 Alnylam Business Overview
11.4.3 Alnylam Familial Amyloid Polyneuropathy Introduction
11.4.4 Alnylam Revenue in Familial Amyloid Polyneuropathy Business (2019-2024)
11.4.5 Alnylam Recent Development
11.5 Corino Therapeutics
11.5.1 Corino Therapeutics Company Detail
11.5.2 Corino Therapeutics Business Overview
11.5.3 Corino Therapeutics Familial Amyloid Polyneuropathy Introduction
11.5.4 Corino Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2019-2024)
11.5.5 Corino Therapeutics Recent Development
11.6 Proclara Bioscience
11.6.1 Proclara Bioscience Company Detail
11.6.2 Proclara Bioscience Business Overview
11.6.3 Proclara Bioscience Familial Amyloid Polyneuropathy Introduction
11.6.4 Proclara Bioscience Revenue in Familial Amyloid Polyneuropathy Business (2019-2024)
11.6.5 Proclara Bioscience Recent Development
11.7 Arcturus Therapeutics
11.7.1 Arcturus Therapeutics Company Detail
11.7.2 Arcturus Therapeutics Business Overview
11.7.3 Arcturus Therapeutics Familial Amyloid Polyneuropathy Introduction
11.7.4 Arcturus Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2019-2024)
11.7.5 Arcturus Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
